|
|
|
| Gene chip analysis of synovial macrophages in rheumatoid arthritis |
| TONG Ye1， WU Zhen-fang2， WANG Yu-xiang2， XU Hai-dong2 |
| (1. Faculty of Graduates， Bengbu Medical College， Bengbu Anhui 233000； 2. Department of Orthopedics, General Hospital of Eastern Theater Command， Nanjing Jiangsu 210002， China）
|
|
|
|
|
Abstract Objective: To identify key genes of rheumatoid arthritis (RA) in order to better understand the underlying pathogenesis of RA. Methods: Differential expression genes (DEGs) in RA synovial macrophages were identified by comprehensive analysis of expression profiles. To explore the potential biological role of DEGs in RA, functional annotation, proteinprotein interaction (PPI) network construction and core gene search were used. The RNA expression level of DEGs in peripheral blood of RA was validated in GSE17755 dataset. Results: Compared with the control group, 489 DEGs were identified in synovial macrophages of RA patients, including 359 upregulated genes and 130 downregulated genes. DEGs are highly enriched in inflammatory response regulation, chemokine receptor binding and tumor necrosis factor signaling pathway. STAT1,CXCL10,FPR2,ITGAM,PPBP,IRF7,CCL5,OASL,OAS3 and IRF1 are the hub genes in the PPI network of DEGs. The expression of 9 core genes except FPR2 in the GSE17755 dataset was detected and found that the expression levels of STAT1, PPBP and OASL in peripheral blood cells of RA patients were significantly upregulated, while ITGAM, IRF7, CCL5 and IRF1 were downregulated. Conclusion: STAT1, OASL and other genes may play an important role in RA diseases.
|
|
Received: 18 June 2019
|
|
|
|
| ［1］Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative\[J\]. Ann Rheum Dis,2010,69(9):1580-1588.［2］Challal S, Minichiello E, Boissier MC, et al. Cachexia and adiposity in rheumatoid arthritis. Relevance for disease management and clinical outcomes\[J\]. Joint Bone Spine,2016,83(2):127-133.［3］Choquette D, Bessette L, Alemao E, et al. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata(R) clinical database and registry\[J\]. Arthritis Res Ther,2019,21(1):138.［4］Crofford LJ. Use of NSAIDs in treating patients with arthritis\[J\]. Arthritis Res Ther,2013,15(Suppl 3)：s2.［5］Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies\[J\]. Nat Rev Rheumatol,2016,12(1):49-62.［6］Mandelin AM 2nd, Homan PJ, Shaffer AM, et al. Transcriptional profiling of synovial macrophages using minimally invasive ultrasoundguided synovial biopsies in rheumatoid arthritis\[J\]. Arthritis Rheumatol,2018,70(6):841-854.［7］Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context of rheumatoid arthritis\[J\]. Nat Rev Rheumatol,2016,12(8):472-485.［8］Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters\[J\]. OMICS,2012,16(5):284-287.［9］ArmasGonzalez E, DominguezLuis MJ, DiazMartin A, et al. Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis\[J\]. Arthritis Res Ther,2018,20(1):114.［10］Zhao G, Mi JY, Pan XY, et al. Correlations between CXCL13, IL24 genes and wrist arthritis\[J\]. Eur Rev Med Pharmacol Sci,2018,22(1):25-30.［11］Hu X, Tang J, Zeng G, et al. RGS1 silencing inhibits the inflammatory response and angiogenesis in rheumatoid arthritis rats through the inactivation of Tolllike receptor signaling pathway\[J\]. J Cell Physiol,2019,234(11):20432-20442. |
|
|
|
2019, Vol. 29 
